Reviva将在2025年CNS峰会上发布关于Brilaroxazine在精神分裂症中负面症状的数据,该数据来自于第三阶段Recover双盲及开放标签延伸试验。
Reviva将在2025年CNS峰会上发布关于Brilaroxazine在精神分裂症中负面症状的数据,该数据来自于第三阶段Recover双盲及开放标签延伸试验。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.